THERAPY: Immunotherapy for T1DM—targeting innate immunity

    loading  Checking for direct PDF access through Ovid

Abstract

Two trials have assessed the use of canakinumab and anakinra in patients with new-onset type 1 diabetes mellitus (T1DM). Although fairly safe, the drugs were not efficacious in terms of halting the decline in β-cell function. Is this the end of the line for targeting IL-1 in T1DM?

Related Topics

    loading  Loading Related Articles